McKesson stock soars to all-time high of $667.08 amid robust growth

McKesson Corporation (NYSE:MCK) stock has reached an unprecedented peak, touching an all-time high of $667.08. According to InvestingPro data, the company’s financial health score is rated as "GREAT," with particularly strong momentum metrics. The stock appears slightly undervalued based on InvestingPro’s Fair Value analysis. This milestone underscores a period of significant growth for the healthcare services and information technology company, reflecting investor confidence and a robust performance in the healthcare sector. Over the past year, McKesson’s stock has witnessed a remarkable ascent, with a 1-year total return of 25.64% and an even more impressive six-month gain of nearly 31%. This surge in stock value is indicative of the company’s strong financial health and its ability to adapt and thrive in a rapidly evolving industry landscape. InvestingPro subscribers have access to 14 additional exclusive insights about McKesson, including detailed analysis of its dividend history, market position, and future growth potential.

In other recent news, McKesson Corporation reported its third-quarter earnings and revenue, which did not meet analyst expectations. The company posted an adjusted earnings per share of $8.03, falling short of the consensus estimate of $8.27, with revenue reaching $95.29 billion, slightly below the forecasted $95.77 billion. Despite this, McKesson raised its full-year earnings guidance, anticipating an adjusted EPS range of $32.55 to $32.95, with the midpoint exceeding analyst expectations. The U.S. Pharmaceutical (TADAWUL:2070) segment, a significant contributor, saw a 19% revenue increase, driven by higher prescription volumes and oncology platform growth.

Additionally, McKesson has announced plans to acquire a controlling interest in PRISM Vision Holdings LLC for $850 million and Florida Cancer Specialists & Research Institute for $2.5 billion, reflecting its strategy to expand in specialty services. S&P Global Ratings revised McKesson’s outlook to positive, affirming a ’BBB+’ rating, citing anticipated growth in its U.S. pharmaceutical segment and prescription technology business. Citi analyst Daniel Grosslight raised the stock price target to $685, maintaining a Buy rating, acknowledging the strong performance in McKesson’s pharmaceutical segment despite a mixed quarter. The company’s updated guidance reflects its ability to navigate challenges while leveraging robust pharmaceutical distribution operations.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.